[ Price : $8.95]
FDA grants Heidelberg Pharma a fast track designation for HDP-101 (pamlectabart tismanitin), the companys lead antibody drug conju...[ Price : $8.95]
Ventyx Biosciences reveals positive Phase 2 data for its oral NLRP3 inhibitor VTX3232 in patients with obesity and cardiovascular ...[ Price : $8.95]
FDA approves a GSK BLA for Blenrep (belantamab mafodotin-blmf) in combination with bortezomib (Velcade) and dexamethasone for trea...[ Price : $8.95]
FDA publishes a guidance with its latest questions and answers on the implementation of regulations covering expanded access to in...[ Price : $8.95]
Tango Therapeutics reports that new data from its ongoing Phase 1-2 study of vopimetostat (TNG462) showed early signs of efficacy ...[ Price : $8.95]
A ProPublica investigative report faults FDA for blocking information about foreign-made generic drugs that could help patients, d...[ Price : $8.95]
The CDER Office of New Drugs publishes a MAPP on the regulatory basis for refusing to file an NDA, sNDA, BLA, or sBLA.[ Price : $8.95]
FDA publishes the checklists used by CDER reviewers to determine if an NDA or BLA can be accepted for filing.